Phase III trial of TAS 102 (Taiho) for Colorectal Cancer begins in June

A global Phase III clinical trial for the novel combination antimetabolite TAS 102, from Taiho, to treat metastatic Colorectal Cancer will begin in June. The trial, named RECOURSE, is a randomized, double-blind, placebo-controlled Phase III trial that compares TAS 102 with best supportive care to investigate the efficacy and safety of TAS 102 when administered to patients with advanced recurrent Colorectal Cancer that is both unresectable and relapsed/refractory to standard chemotherapies. Standard chemotherapies include fluoropyrimidines, irinotecan, oxaliplatin, bevacizumab and, in the case of patients whose tumor harbors the wild-type KRAS gene, an anti-EGFR monoclonal antibody. The primary endpoint is overall survival. Eight hundred patients around the world will be enrolled into the trial, beginning in Japan in June.